Skin Substitute and Wound Care Billing Audits: Documentation, Medical Necessity, and the 2026 Crackdown

How the 2026 Medicare payment overhaul, withdrawn LCDs, WISeR prior authorization, OIG findings, and DOJ enforcement have reshaped skin substitute and wound care audits, and what documentation providers need to support medical necessity.

KNOWLEDGE CENTER

11/15/202612 min read

Few areas of Medicare spending have grown as fast, or drawn as much enforcement attention, as skin substitutes. These products, also called cellular and tissue-based products, are applied to chronic wounds such as diabetic foot ulcers and venous leg ulcers that have not healed with standard care. According to federal investigators, Medicare spending on skin substitutes grew from about $256 million in 2019 to more than $10 billion in 2024, while patient volume roughly doubled. In September 2025, the HHS Office of Inspector General (OIG) issued a report titled Medicare Part B Payment Trends for Skin Substitutes Raise Major Concerns About Fraud, Waste, and Abuse.

The government responded on several fronts. Effective January 1, 2026, the CY 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System final rules reclassified most skin substitutes as incident-to supplies paid at a single rate of about $127 per square centimeter, replacing product-specific payments that had reached more than $2,000 per square centimeter. The WISeR prior authorization model added skin substitutes in certain states. DOJ made wound care a centerpiece of its June 2026 National Health Care Fraud Takedown. Meanwhile, the Medicare Administrative Contractors withdrew the uniform skin substitute coverage policies that had been scheduled to take effect on January 1, 2026, leaving a patchwork of coverage rules.

This article explains the 2026 payment and coverage landscape, what auditors look for, and the documentation wound care providers need. It is educational and not legal advice. Because coverage policies differ by MAC and continue to change, providers should confirm current requirements with their MAC and experienced healthcare counsel.

The 2026 Payment Overhaul

From Biologicals to Incident-to Supplies

Before 2026, most skin substitutes were paid as biologicals based on average sales price plus a percentage, which produced widely varying, product-specific payment rates. In the CY 2026 Physician Fee Schedule final rule, CMS finalized a policy to pay for most skin substitute products as incident-to supplies when used as part of a covered application procedure in the physician office setting or the hospital outpatient department. Products are grouped by their FDA regulatory status, and for 2026 CMS set a single payment rate of approximately $127 per square centimeter for all three groups, before geographic adjustment. CMS later issued a technical correction adjusting the rate slightly. Skin substitutes licensed as biologics under section 351 of the Public Health Service Act continue to be paid under the average sales price methodology.

Expected Impact

CMS said the change was expected to reduce Medicare spending on skin substitutes by nearly 90 percent, and projected a reduction in gross fee-for-service spending of about $19.6 billion in 2026. CMS cited abusive pricing practices and the use of products with limited evidence of clinical value as drivers of the spending increase.

What the Payment Change Means for Audits

The flat rate reduces the financial incentive to use high-priced products, but it does not reduce audit risk for prior years, when payments were much higher. Overpayment exposure for 2023 through 2025 claims can be very large, and those claims remain subject to review. The new rate also makes product waste more consequential, since providers can no longer rely on high per-unit payments to absorb inefficiency.

Coverage: The Withdrawn LCDs and What Remains

The Withdrawn Uniform LCDs

In November 2024, all seven Part B MACs finalized uniform Local Coverage Determinations for skin substitutes used to treat diabetic foot ulcers and venous leg ulcers. The LCDs would have limited coverage to products with sufficient evidence, required documented failure of at least four weeks of standard care, set limits on the number of applications per wound episode, and imposed detailed documentation requirements. The effective date was delayed twice, to January 1, 2026. On December 24, 2025, CMS announced that the MACs were withdrawing the LCDs effective immediately.

Legacy Policies

As a result of the withdrawal, three Part B MACs, Novitas, First Coast, and CGS, kept their existing skin substitute coverage policies in effect, while the other four Part B MACs continued to have no published skin substitute LCD. In jurisdictions without an LCD, claims are evaluated under the general Medicare reasonable and necessary standard and any applicable billing and coding articles.

The Reasonable and Necessary Standard Still Applies

The absence of an LCD does not mean anything is covered. Every claim must still be reasonable and necessary for the diagnosis or treatment of the patient's condition, supported by the medical record, and billed correctly. Auditors in jurisdictions without an LCD often apply clinical standards drawn from medical literature, prior LCDs, and the withdrawn uniform LCDs as indicators of reasonable care.

WISeR Prior Authorization

CMS's Wasteful and Inappropriate Service Reduction (WISeR) Model, which began January 1, 2026, uses technology-enabled prior authorization or prepayment review for selected services in six states. Skin substitute application for diabetic foot ulcers and venous leg ulcers is included in the model, but after the LCD withdrawal, the skin substitute component took effect only in states with an active LCD, reportedly New Jersey, Ohio, Oklahoma, and Texas. Providers in those states should confirm whether their services are subject to WISeR review.

What OIG Found

OIG's September 2025 report described skin substitutes as particularly vulnerable to questionable billing and fraud schemes. OIG flagged utilization patterns associated with fraud risk, including:

• Applying skin substitutes on a patient's first visit without any prior attempt at conservative treatment.

• Applying skin substitutes to wounds that were not chronic or did not require them.

• Using quantities exceeding the size of the wound.

• High numbers of applications per patient.

• Rapid growth in billing by individual providers, particularly in home and mobile settings.

• Concentration of billing for hospice patients and patients with limited life expectancy.

These patterns are now standard data analytics triggers for MACs, Unified Program Integrity Contractors, and law enforcement.

The Enforcement Landscape

DOJ's 2026 Takedown

On June 23, 2026, DOJ announced charges against 11 defendants, including a company executive and eight medical professionals, across six federal districts in connection with more than $2 billion in alleged fraudulent claims for amniotic wound allografts. DOJ said its Health Care Fraud Unit's data analytics team detected a spike in payments for allografts that led to the investigations. Alleged conduct included kickbacks to providers, medically unnecessary applications, applications to infected, healed, or superficial wounds, applications to areas exceeding the wound size, falsified medical records, and exploitation of elderly and hospice patients.

False Claims Act Settlements

DOJ has also resolved civil False Claims Act cases involving skin substitutes, including cases alleging medically unnecessary applications and kickback arrangements. In at least one case, the United States filed its complaint without a whistleblower, highlighting DOJ's willingness to pursue skin substitute cases on its own.

Administrative Actions

CMS has used administrative tools, such as letters notifying high billers of unusual billing patterns, payment suspensions, and revocations. DOJ officials have said that a large share of outlier billers stopped billing skin substitutes after receiving CMS notices.

What Auditors Look For

Wound Characteristics

Auditors check whether the wound was appropriate for a skin substitute:

• Type of wound, such as diabetic foot ulcer, venous leg ulcer, or other chronic wound.

• Wound duration and chronicity.

• Wound depth and tissue involvement.

• Absence of infection, osteomyelitis, or untreated underlying conditions.

• Adequate blood flow, documented through vascular assessment where appropriate.

Standard of Care Before Application

Auditors look for documentation that appropriate standard wound care was provided and failed before a skin substitute was used, including:

• Debridement of necrotic tissue.

• Moisture-balanced dressings.

• Offloading for diabetic foot ulcers.

• Compression therapy for venous leg ulcers.

• Infection control.

• Glycemic control and management of underlying conditions.

• Measurement of wound response over a defined period, often at least four weeks.

Wound Measurements

Accurate measurements are critical. Records should document length, width, and depth at each visit, ideally with photographs. Measurements support both the decision to apply a skin substitute and the quantity billed.

Product Selection and Quantity

Auditors compare the product size billed with the wound size. The product used should be the smallest size that adequately covers the wound. Documentation should record the product name, lot or serial number, size, amount applied, and amount wasted.

Wastage

Medicare rules on discarded amounts have changed with the 2026 reclassification. Providers should follow current CMS and MAC guidance on whether and how wastage is billed and documented, and avoid systematically using oversized products.

Application Frequency and Number

Auditors review the number and frequency of applications, whether the wound was improving, and whether continued applications were justified. Continued application to a wound that is not responding, or to a healed wound, is a common finding.

Progress Documentation

Each visit note should document the wound's status, measurements, response to treatment, and the rationale for continuing or changing therapy.

Ordering and Supervision

For incident-to services, auditors check that supervision requirements were met and that the services were furnished by appropriately licensed personnel. DOJ cases have involved services allegedly provided by unlicensed individuals or billed under providers who were not present.

Setting

Skin substitute applications in home, mobile, and hospice settings have drawn particular scrutiny. Providers in these settings should be prepared to show that the setting was appropriate and that services met all requirements.

Kickbacks and Financial Relationships

Many enforcement cases involve financial relationships between manufacturers, distributors, and providers, such as payments disguised as consulting or marketing fees, rebates that reward volume, or arrangements that share the spread between acquisition cost and Medicare payment. The federal Anti-Kickback Statute prohibits offering or receiving remuneration to induce referrals or purchases of items paid by federal health care programs. Providers should review all relationships with skin substitute manufacturers and distributors with counsel.

Building Audit-Ready Wound Care Documentation

• Use structured wound assessment templates that capture wound type, duration, measurements, depth, tissue type, infection status, and vascular status.

• Document standard of care measures and response over time before using skin substitutes.

• Photograph wounds at each visit where feasible.

• Record product details, size, amount applied, and wastage.

• Document the rationale for each application and for continued treatment.

• Track wound outcomes and stop applications when wounds heal or fail to respond.

• Monitor billing patterns against peers.

• Review financial relationships with manufacturers and distributors.

Responding to a Skin Substitute Audit

• Respond to every additional documentation request by the deadline with complete wound care records for the episode, not just the application visits.

• Include records of standard care before the first application, measurements, photographs, product documentation, and progress notes.

• Review findings against the applicable LCD, billing and coding article, or the reasonable and necessary standard.

• Challenge sampling and extrapolation where used.

• Appeal through the Medicare appeals process, beginning with redetermination within 120 days.

• Engage counsel immediately if UPIC involvement, payment suspension, subpoenas, or civil investigative demands arise.

Common Mistakes

• Applying skin substitutes without documented standard care.

• Inconsistent or missing wound measurements.

• Billing product sizes much larger than the wound.

• Continuing applications without documented progress.

• Applying to healed or infected wounds.

• Relying on distributor-provided templates or billing advice.

• Ignoring financial relationships that could implicate the Anti-Kickback Statute.

Documentation by Phase of the Wound Episode

Auditors rarely look at a single application note in isolation. They reconstruct the entire wound episode, from the first encounter to healing or discharge, and ask whether each step made clinical sense. Organizing documentation by phase helps clinicians see what reviewers expect at each point.

Initial Evaluation

The first wound visit should establish the baseline that every later decision depends on. The note should identify the wound's location, etiology, and duration, and record length, width, and depth measured in a consistent way. It should describe the wound bed, including granulation, slough, eschar, and exposed structures, along with drainage, odor, and the condition of surrounding skin. The clinician should document signs of infection and whether osteomyelitis has been considered or ruled out, the patient's vascular status, including pulses and, where indicated, ankle-brachial index or other noninvasive studies, and relevant comorbidities such as diabetes control, smoking, nutrition, and edema. The plan of care should describe the standard therapies being started.

Standard Care Period

During the period of conservative care, each visit should record measurements, the treatments provided, patient adherence, and the wound's response. For diabetic foot ulcers, documentation of offloading is critical, including the device used and whether the patient is using it. For venous leg ulcers, documentation of compression, including the type and level, is equally important. If a patient cannot tolerate offloading or compression, the record should say so and describe alternatives. Reviewers often deny claims when the record shows only one or two visits before the first application, or when measurements suggest the wound was already improving.

Decision to Apply a Skin Substitute

The note for the first application should explain why the clinician concluded that the wound had failed to respond adequately to standard care, typically by comparing current measurements with baseline. It should confirm that infection has been controlled, that perfusion is adequate, and that the wound bed has been prepared, usually through debridement. It should identify the specific product selected and explain why that product and size are appropriate for this wound.

Application Visits

Each application note should include pre-application measurements, the debridement performed, the product name, size, and lot or serial number, the amount applied and any amount discarded, the method of securing the product, and the secondary dressing. Photographs taken before application are especially persuasive. The note should continue to document standard care measures such as offloading and compression, since a skin substitute is an adjunct to, not a replacement for, standard care.

Reassessment and Discontinuation

At regular intervals, the clinician should assess whether the wound is responding. If measurements show meaningful improvement, continued applications may be justified. If the wound has stalled or worsened, the record should explain the clinical reasoning for continuing, changing products, or stopping, and should consider referral or further workup. When the wound heals, applications should stop, and the final note should document closure.

Coding and Billing Considerations

Skin substitute claims involve two components: the application procedure and the product itself. Application procedures are billed with CPT codes that distinguish by anatomic location and wound surface area, with add-on codes for additional area. The product is reported with a HCPCS Q code or other applicable code, in units that correspond to square centimeters. Auditors check that the procedure code reflects the actual wound location and size, that product units reflect the product size used, and that the two components are consistent with each other and with the measurements in the record.

Because the 2026 payment methodology changed how most products are paid, coding and billing staff should confirm current requirements for reporting products, discarded amounts, and modifiers with their MAC. Organizations should also confirm that their charge masters and billing systems were updated for January 1, 2026, since claims processed under outdated logic can generate errors that look like overbilling. Hospital outpatient departments should review how skin substitute payment interacts with OPPS packaging rules, and physician offices should confirm that incident-to supply billing meets all supervision and documentation requirements.

Building an Internal Audit Program for Wound Care

An internal audit program allows an organization to find and correct problems before an external reviewer does. A practical program includes several elements:

• Sampling a set number of wound episodes each quarter, weighted toward high-volume clinicians, sites, and products.

• Reviewing each sampled episode from the initial evaluation through discharge, using a checklist that mirrors the phases described above.

• Comparing product units billed with documented wound sizes and flagging variances.

• Tracking applications per episode and healing rates by clinician and site.

• Reviewing a sample of claims for home, mobile, and hospice patients separately, given heightened scrutiny of those settings.

• Reporting results to compliance leadership, providing targeted education, and re-auditing clinicians with findings.

• Working with counsel to evaluate whether findings create a reportable overpayment under the 60-day rule.

Data monitoring should complement chart review. Organizations can use their own claims data, and where available CMS comparative billing reports, to see how their utilization compares with peers. An outlier position does not prove that anything is wrong, but it does indicate what an external reviewer is likely to see and where documentation needs to be strongest.

Myths About Skin Substitute Billing

Myth: The LCD Withdrawal Means There Are No Coverage Rules

Legacy LCDs remain in three MAC jurisdictions, and all claims must meet the reasonable and necessary standard.

Myth: Lower Payment Rates Mean Lower Audit Risk

Prior-year claims paid at much higher rates remain subject to review, and enforcement continues.

Myth: Distributors Handle Compliance

Providers are responsible for the claims they submit, regardless of distributor advice.

Myth: Only Fraudulent Providers Are Audited

Data analytics flag outlier patterns, and legitimate providers with documentation gaps can face large overpayment demands.

Questions Leadership Should Ask

• Do our wound records document standard care before every first application?

• Are measurements and photographs consistent at every visit?

• Do product sizes match wound sizes?

• Which coverage policy applies in our MAC jurisdiction?

• Are we subject to WISeR prior authorization?

• Have counsel reviewed our relationships with manufacturers and distributors?

Key Takeaways

• Medicare skin substitute spending grew from about $256 million in 2019 to more than $10 billion in 2024, prompting OIG, CMS, and DOJ action.

• Since January 1, 2026, most skin substitutes are paid as incident-to supplies at about $127 per square centimeter.

• The uniform 2026 LCDs were withdrawn, leaving legacy LCDs at three MACs and the reasonable and necessary standard everywhere.

• DOJ's 2026 takedown charged 11 defendants in alleged amniotic allograft schemes exceeding $2 billion, and civil and administrative enforcement continues.

• Documentation of wound characteristics, standard care, measurements, product use, and progress is the foundation of audit defense.

How HealthBridge Can Help

HealthBridge helps wound care providers, hospital outpatient departments, and post-acute organizations strengthen skin substitute documentation and respond to audits. Our team can audit wound care records against coverage policies and the reasonable and necessary standard, build structured documentation templates, analyze billing patterns, and prepare responses and appeals. We also help organizations review manufacturer and distributor relationships with counsel and prepare for WISeR prior authorization where applicable. If your organization provides skin substitutes, please get in touch with us. We will be happy to help you with this topic.

References

• HHS Office of Inspector General. Medicare Part B Payment Trends for Skin Substitutes Raise Major Concerns About Fraud, Waste, and Abuse (September 2025). https://oig.hhs.gov/reports/all/2025/medicare-part-b-payment-trends-for-skin-substitutes-raise-major-concerns-about-fraud-waste-and-abuse/

• Centers for Medicare & Medicaid Services. CMS Modernizes Payment Accuracy, Significantly Cuts Spending Waste (October 31, 2025). https://www.cms.gov/newsroom/press-releases/cms-modernizes-payment-accuracy-significantly-cuts-spending-waste

• Centers for Medicare & Medicaid Services. Calendar Year 2026 Medicare Physician Fee Schedule Final Rule Fact Sheet (CMS-1832-F). https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule-cms-1832-f

• Centers for Medicare & Medicaid Services. Upcoming Update to Final Local Coverage Determinations for Certain Skin Substitutes (December 24, 2025). https://cms.gov/newsroom/fact-sheets/upcoming-update-final-local-coverage-determinations-lcds-certain-skin-substitutes

• Federal Register. Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model (July 1, 2025). https://www.federalregister.gov/documents/2025/07/01/2025-12195/medicare-program-implementation-of-prior-authorization-for-select-services-for-the-wasteful-and

• CGS Administrators (CMS contractor). CY 2026 Physician Fee Schedule Final Rule summary. https://cgsmedicare.com/articles/cope189468.html

• U.S. Department of Justice. National Health Care Fraud Takedown (June 23, 2026). https://www.justice.gov/opa/pr/national-health-care-fraud-takedown-2026

• U.S. Department of Justice, Criminal Division, Fraud Section. Health Care Fraud Unit. https://www.justice.gov/criminal/criminal-fraud/health-care-fraud-unit

• Electronic Code of Federal Regulations. 42 CFR 410.26, Services and supplies incident to a physician's professional service. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-410/subpart-B/section-410.26

• U.S. Code. 42 U.S.C. 1395y(a)(1)(A), Reasonable and necessary exclusion. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1395y

• U.S. Code. 42 U.S.C. 1320a-7b(b), Anti-Kickback Statute. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1320a-7b

Some or all of the services described herein may not be permissible for HealthBridge US clients and their affiliates or related entities.

The information provided is general in nature and is not intended to address the specific circumstances of any individual or entity. While we strive to offer accurate and timely information, we cannot guarantee that such information remains accurate after it is received or that it will continue to be accurate over time. Anyone seeking to act on such information should first seek professional advice tailored to their specific situation. HealthBridge US does not offer legal services.

HealthBridge US is not affiliated with any department of public health agencies in any state, nor with the Centers for Medicare & Medicaid Services (CMS). We offer healthcare consulting services exclusively and are an independent consulting firm not affiliated with any regulatory organizations, including but not limited to the Accrediting Organizations, the Centers for Medicare & Medicaid Services (CMS), and state departments. HealthBridge is an anti-fraud company in full compliance with all applicable federal and state regulations for CMS, as well as other relevant business and healthcare laws. The badges, icons, and achievement graphics displayed on this website represent proprietary performance metrics, volume milestones, and internal corporate recognition issued exclusively by our corporate affiliate network at SummitRidge. These visual markers are utilized solely as historical indicators of enterprise growth, operational longevity, and volume-based milestones cleared within our shared corporate ecosystem.

© 2026 HealthBridge US, a California corporation. All rights reserved.

For more information about the structure of HealthBridge, visit www.myhbconsulting.com/governance

Legal

Resources